The Latest Breaking News from Relay rapeutics

Relay Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Over the past 3 months, 4 analysts have published their opinion on Relay Therapeutics (NASDAQ:RLAY) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Upgrades

Relay Therapeutics (NASDAQ:RLAY) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Relay Therapeutics will report an earnings per share (EPS) of $-0.62.